Cannabinoid receptor systems: therapeutic targets for tumour intervention

Bibliography

• MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned DNA. Nature (1990) 346:561–564.
   PubMed Web of Science ®Google Scholar
• •Cloning of the CBI receptor.
   Google Scholar
• MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61–65.
   PubMed Web of Science ®Google Scholar
• •Cloning of the CB2 receptor.
   Google Scholar
• BOUABOULA M, POINOT-CHAZEL C, BOURRIE B et al.: Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor. Biochern. J. (1995) 312:637–641.
   PubMed Web of Science ®Google Scholar
• PERT WEE RG: Pharmacology of cannabinoid CB]. and CB2 receptors. Pharmacol Ther. (1997) 74:129–180.
   PubMed Web of Science ®Google Scholar
• ••Classification of cannabinoid receptors by aleading expert.
   Google Scholar
• HOWLETT AC, BARTH F, BONNER TI et al.: International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 54:161–202.
   Google Scholar
• ••An all-encompassing and thorough review ofcannabinoid receptor pharmacology to date.
   Google Scholar
• DI MARZO V, MELCK D, DE PETROCELLIS D, BISOGNO T: Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat. (2000) 61:43–61.
   PubMed Web of Science ®Google Scholar
• KLEIN TW, NEWTON C, LARSEN Ket al.: The cannabinoid system andimmune modulation. J. Leukoc. Biol. (2003) 74:486–496.
   Google Scholar
• ROTH MD, BALDWIN GC, TASHKIN DP: Effects of A-9-tetrahydrocannabinol on human immune function and host defense. Chem. Phys. Lipids (2002) 121:229–239.
   PubMed Web of Science ®Google Scholar
• GUZMAN M, SANCHEZ C, GALVE-ROPERH I: Cannabinoids and cell fate. Pharmacol Ther (2002) 95:175–184.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive and succinct reviewencompassing excellent coverage of signal transduction pathways.
   Google Scholar
• GUZMAN M, SANCHEZ C, GALVE-ROPERH I: Control of the cell survival/death decision by cannabinoids. J Ma. Med. (2001) 78:613–625.
   PubMed Web of Science ®Google Scholar
• VAN DER STELT M, VELTHUIS WB, MACCARRONE M et al: Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol. Neurobiol (2002) 26:317–346.
   PubMed Web of Science ®Google Scholar
• GRUNDY RI, RABUFFETTI M, BELTRAMO M: Cannabinoids and neuroprotection. Mol. Neurobiol (2001) 24:29–52.
   PubMed Web of Science ®Google Scholar
• MECHOULAM R: Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukot. Essent. Fatty Adds (2002) 66:93–99.
   PubMed Web of Science ®Google Scholar
• NAGAYAMA T, SINOR AD, SIMON RP et al: Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures../. Neurosci (1999) 19:2987–2995.
   PubMed Web of Science ®Google Scholar
• BIFULCO M, DI MARZO V: Targeting the endocannabinoid system in cancer therapy: a call for further research. Nature (2002) 8:547–550.
   Web of Science ®Google Scholar
• ••A timely and succinct review of cannabinoids as anticancer agents.
   Google Scholar
• PAROLARO D, MASSI P, RUBINO T, MONTI E: Endocannabinoids in the immune system and cancer. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:319–332.
   PubMed Web of Science ®Google Scholar
• ••An excellent review evaluating the role ofendocannabinoids as antitumour agents.
   Google Scholar
• HUFFMAN JW, YU S, SHOWALTER V et al: Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. Med. Chem. (1996) 39:3875–3877.
   Web of Science ®Google Scholar
• HUFFMAN JW, LIDDLE J, YU S et al.: 3-(1',1'-Dimethylbuty0-1-deoxy-A8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem. (1999) 7:2905–2914.
   PubMed Web of Science ®Google Scholar
• HANUS L, BREUER A, TCHILIBON S et al: HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Nati Acad. Sci. USA (1999) 96:14228–14233.
   PubMed Web of Science ®Google Scholar
• PERT WEE RG, ROSS RA: Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Adds (2002) 66:101–121.
   PubMed Web of Science ®Google Scholar
• ••An excellent review by a leading expert.
   Google Scholar
• COMPTON DR, GOLD LH, WARD SJ, BALSTER RL, MARTIN BR: Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from A9-tetrahydrocannabinol. Pharmacol. Exp. Ther (1992) 263:1118–1126.
   PubMed Web of Science ®Google Scholar
• D'AMBRA TE, ESTEP KG, BELL MR et al.: Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl) indole agonists of the cannabinoid receptor. J. Med. Chem. (1992) 35:124–135.
   Google Scholar
• EISSENSTAT MA, BELL MR, D'AMBRA TE et al.: Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. I Med. Chem. (1995) 38:3094–3105.
   Google Scholar
• IBRAHIM MM, DENG H, ZVONOK A et al: Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. USA (2003) 100:10529–10533.
   PubMed Web of Science ®Google Scholar
• MAULER F, MITTENDORF J, HORVATH E, DE VRY J: Characterization of the diarylether sulfonylester - (R)-3-(2-hydroxymethylindany1-4-oxy)phenyl-4,4,4-trifluoro-l-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. Pharmacol. Exp. Ther (2002) 302:359–368.
   PubMed Web of Science ®Google Scholar
• MECHOULAM R, FRIDE E, DI MARZO V: Endocannabinoids. Eur. Pharmacol. (1998) 359:1–8.
   PubMed Web of Science ®Google Scholar
• DI MARZO V: `Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta (1998) 1392:153–175.
   PubMed Web of Science ®Google Scholar
• DEVANE WA, DYSARZ FA, JOHNSON MR et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946–1949.
   PubMed Web of Science ®Google Scholar
• •Isolation of the first putative endogenous ligand.
   Google Scholar
• HILLARD CJ, MANNA S, GREENBERG MJ et al: Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CBI.). Pharmacol. Exp. Ther. (1999) 289:1427–1433.
   PubMed Web of Science ®Google Scholar
• MECHOULAM R, BEN-SHABAT S, HANUS S et al.: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. (1995) 50:83–90.
   PubMed Web of Science ®Google Scholar
• SUGIURA T, KONDO S, SUKAGAWA A et al.: 2-arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. (1995) 215:89–97.
   PubMed Web of Science ®Google Scholar
• HANUS L, ABU-LAFI S, FRIDE E et al.:2-arachidonylglycerol ether, an endogenous agonist of the cannabinoid CBI. receptor. Proc. Nati Acad. Li. USA (2001) 98:3662–3665.
   PubMed Web of Science ®Google Scholar
• OKA S, TSUCHIE A, TOKUMURA A et al.: Ether-linked analogue of 2-arachidonylglycerol (noladin ether) was not detected in the brains of various mammalian species. J. Neurochem. (2003) 85:1374–1381.
   PubMed Web of Science ®Google Scholar
• RINALDI-CARMONA M, BARTH F, HEAULME M et at: 5R141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240–244.
   PubMed Web of Science ®Google Scholar
• FELDER CC, JOYCE KE, BRILEY EM et al: LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther (1998) 284:291–297.
   PubMed Web of Science ®Google Scholar
• BOUABOULA M, PERRACHON S, MILLIGAN L et al: A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptoriligand interactions. J. Biol. Chem. (1997) 272:22330–22339.
   Google Scholar
• RINALDI-CARMONA M, BARTH F, MILLAN J et al: 5R144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. (1998) 284:644–650.
   PubMed Web of Science ®Google Scholar
• ROSS RA, BROCKIE HC, STEVENSON LA et al: Agonist-inverse agonist characterization at CBI. and CB2 cannabinoid receptors of L759633, L759656 and AM630. BE I Pharmacol. (1999) 126:665–672.
   Google Scholar
• PERTWEE RG: Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. (1999) 6:635–664.
   PubMed Web of Science ®Google Scholar
• DI MARZO V, FONTANA A, CADAS H et al.: Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 372:686–691.
   PubMed Web of Science ®Google Scholar
• HILLARD CJ: Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat. (2000) 61:3–18.
   PubMed Web of Science ®Google Scholar
• RAKHSHAN F, DAY TA, BLAKELY RD, BARKER EL: Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3. I Pharmacol. Exp. Ther (2000) 292:960–967.
   PubMed Web of Science ®Google Scholar
• BISOGNO T, MAURELLI S, MELCK D, DE PETROCELLIS L, DI MARZO V: Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes. I Biol. Chem. (1997) 272:3315–3323.
   Web of Science ®Google Scholar
• CRAVATT BE GIANG DK, MAYFIELD SP, BOGER DL, LERNER RA, GILULA NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 384:83–87.
   PubMed Web of Science ®Google Scholar
• UEDA N, YAMAMOTO S: Anandamide amidohydrolase (fatty acid amide hydrolase). Prostaglandins Other Lipid Mediat. (2000) 61:19–28.
   PubMed Web of Science ®Google Scholar
• MUNSON AE, HARRIS LS, FRIEDMAN MA, DEWEY WL, CARCHMAN RA: Antineoplastic activity of cannabinoids. J. Natl. Cancerinst. (1975) 55:597–602.
   PubMed Web of Science ®Google Scholar
• WHITE AC, MUNSON JA, MUNSON AE, CARCHMAN RA: Effects of A9-tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. J. Natl. Cancer Inst. (1976) 56:655–658.
   PubMedGoogle Scholar
• CARCHMAN RA, HARRIS LS, MUNSON AE: The inhibition of DNA synthesis by cannabinoids. Cancer Res. (1976) 31:95–100.
   Google Scholar
• MON MJ, JANSING RL, DOGGETT S, STEIN JL, STEIN GS: Influence of A9-tetrahydrocannabinol on cell proliferation and macromolecular biosynthesis in human cells. Biochem. Pharmacol (1978) 27:1759–1765.
   PubMed Web of Science ®Google Scholar
• MAHER EA, FURNARI FB, BACHOO RM et al: Malignant glioma: genetics and biology of a grave matter. Genes Dev. (2001) 15:1311–1333.
   PubMed Web of Science ®Google Scholar
• GALVE-ROPERH I, SANCHEZ C, CORTES ML, DEL PULGAR TG, IZQUIERDO M, GUZMAN M: Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. (2000) 16:313–319.
   Google Scholar
• ••A seminal report signifying the antitumoureffects of cannabinoids in vivo.
   Google Scholar
• BLAZQUEZ C, CASANOVA ML, PLANAS A et al: Inhibition of tumor angiogenesis by cannabinoids. FASEB J. (2003) 17:529–531.
   PubMed Web of Science ®Google Scholar
• PUNIGLIA KM, DECKER SJ: Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl. Acad. Sci. USA (1997) 94:448–452.
   PubMed Web of Science ®Google Scholar
• YORK RD, YAO H, DILLON T et al: Rapl mediates sustained MAP kinase activation induced by nerve growth factor. Nature (1998) 392:622–626.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C, GALVE-ROPERH I, CANOVA C, BRACHET P, GUZMAN M: A9-tetrahydrocannabinol induces apoptosis in C6.9 glioma cells. FEBS Lett. (1998) 436:6–10.
   Google Scholar
• SANCHEZ C, GALVE-ROPERH I, RUEDA D, GUZMAN M: Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the A9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol (1998) 54:834–843.
   PubMed Web of Science ®Google Scholar
• PERRY DK, CARTON J, SHAH AK, MEREDITH F, UHLINGER DJ, HANNUN YA: Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. ./. Biol. Chem. (2000) 275:9078–9084.
   PubMed Web of Science ®Google Scholar
• HUWILER A, KOLTER T, PFEILSCHIFTER J, SANDHOFF K: Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim. Biophys. Acta (2000) 1485:63–99.
   PubMed Web of Science ®Google Scholar
• GUZMAN M, GALVE-ROPERH I, SANCHEZ C: Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol Sci. (2001) 22:19–22.
   PubMed Web of Science ®Google Scholar
• BLAZQUEZ C, SANCHEZ C, DAZA A, GALVE-ROPERH I, GUZMAN M: The stimulation of ketogenesis by cannabinoids in cultured astrocytes defines carnitine palmitoyl transferase I as a new ceramide activated enzyme../. Neurochem. (1999) 72: 1759-1768.
   Google Scholar
• SANCHEZ C, RUEDA D, SEGUI D, GALVE-ROPERH I, LEVADE T, GUZMAN M: The cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein FAN. Mol. Pharmacol (2001) 59:955–959.
   PubMed Web of Science ®Google Scholar
• GOMEZ DEL PULGAR T, VELASCO G,GUZMAN M: The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. .1 (2000) 347:369-373.
   Google Scholar
• RUEDA D, GALVE-ROPERH I, HARO A, GUZMAN M: The CB1 cannabinoid receptor is coupled to the activation of c-Jun-N-terminal kinase. Mol. Pharmacol (2000) 58:814–820.
   PubMed Web of Science ®Google Scholar
• •These fmdings prompt an excellent discussion of the diversity of cannabinoid-mediated signal transduction mechanisms in the determination of cell fate.
   Google Scholar
• HARPER SJ, LOGRASSO P: Signaling for survival and death in neurons. The role of stress-activated kinases, JNK and p38. Cell. Signal. (2001) 13:299–310.
   Google Scholar
• GALVE-ROPERH I, RUEDA D, GOMEZ DEL PULGAR T, VELASCO G, GUZMAN M: Mechanism of extracellular signal-regulated kinase activation by the CBI cannabinoid receptor. Mol. Pharmacol (2002) 62:1385–1392.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C, DE CEBALLOS ML, GOMEZ DEL PULGAR T et al: Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res. (2001) 61:5784–5789.
   PubMed Web of Science ®Google Scholar
• BROWN J, READING SJ, JONES S et al: Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell line T24/83. Lab. Invest. (2000) 80:37–45.
   PubMed Web of Science ®Google Scholar
• DE PETROCELLIS L, MELCK D, PALMISANO A et al.: The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl. Acad. Sci. USA (1998) 95:8375–8380.
   PubMed Web of Science ®Google Scholar
• MELCK D, DE PETROCELLIS L, ORLANDO P et al.: Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology (2000) 141:118–126.
   PubMed Web of Science ®Google Scholar
• MELCK D, RUEDA D, GALVE-ROPERH I, DE PETROCELLIS L, GUZMAN M, DI MARZO V: Involvement of the cAMP-protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett. (1999) 463:235–240.
   PubMed Web of Science ®Google Scholar
• CRAVATT BE PROSPER-GARCIA O, SIUZDAK G et al.: Chemical characterization of a family of brain lipids that induce sleep. Science (1995) 268:1506–1509.
   PubMed Web of Science ®Google Scholar
• BISOGNO T, KATAYAMA K, MELCK D et al: Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells. Eur. Biochem. (1998) 254:634–642.
   PubMedGoogle Scholar
• MECHOULAM R, FRIDE E, HANUS L et al.: Anandamide may mediate sleep induction. Nature (1997) 389:25–26.
   PubMed Web of Science ®Google Scholar
• DE PETROCELLIS L, MELCK D, BISOGNO T, DI MARZO V: Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem. Phys. Lipids (2000) 108:191–209.
   PubMed Web of Science ®Google Scholar
• ••A pioneering review exploring noveltherapeutic targets of the endocannabinoid system.
   Google Scholar
• BISOGNO T, MAURELLI S, MELCK D, DE PETROCELLIS L, DI MARZO V: Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes. ./. Biol. Chem. (1997) 272:3315–3323.
   PubMed Web of Science ®Google Scholar
• LAMBERT DM, DI MARZO V: The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic. Curr. Med. Chem. (1999) 6:757–773.
   PubMed Web of Science ®Google Scholar
• DI MARZO V, MELCK D, ORLANDO P et al.: Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. (2001) 358:249–255.
   PubMed Web of Science ®Google Scholar
• MIMEAULT M, POMMERY N, WATTEZ N, BAILLY C, HENICHART JP: Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate (2003) 56:1–12.
   PubMed Web of Science ®Google Scholar
• RUIZ L, MIGUEL A, DIAZ-LAVIADA I:A9-Tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett. (1999) 458:400–404.
   PubMed Web of Science ®Google Scholar
• KAMIYAMA M, FURUYA Y, TAKIHANA Y et al.: Anandamide and capsaicin inhibit proliferation of human prostate cancer cell via cannabinoid receptor and vanilloid receptor respectively. Eur. Urol. Suppl (2003) 2:36.
   Google Scholar
• BIFULCO M, LAEZZA C, PORTELLA G et al: Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB (2001) 15:2745–2747.
   PubMed Web of Science ®Google Scholar
• PORTELLA G, LAEZZA C, LACCETTI P, DE PETROCELLIS L, DI MARZO M, BIFULCO M: Inhibitory effects of cannabinoid CBI receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. (2003). Epublished ahead of print.
   Google Scholar
• CASANOVA ML, BLAZQUEZ C, MARTINEZ-PALACIO J et al: Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. ./. Clin. Invest. (2003) 111:43–50.
   Google Scholar
• MCKALLIP RJ, LOMBARD C, FISHER Metal: Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood (2002) 100:627–634.
   PubMed Web of Science ®Google Scholar
• DI MARZO V, DE PETROCELLIS L, FEZZA F, LIGRESTI A, BISOGNO T: Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:377–391.
   PubMed Web of Science ®Google Scholar
• SMART D, GUNTHORPE MJ, JERMAN JC et al: The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol (2000) 129:227–230.
   PubMed Web of Science ®Google Scholar
• ZYGMUNT PM, PETERSSON J, ANDERSSON DA et al: Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (1999) 400:452–457.
   PubMed Web of Science ®Google Scholar
• CATERINA MJ, SCHUMACHER MA, TOMINAGA M, ROSEN TA, LEVINE JD, JULIUS D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature (1997) 389:816–824.
   PubMed Web of Science ®Google Scholar
• MACCARRONE M, LORENZON T, BARI M, MELINO G, FINAZZI-AGRO A: Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. ./. Biol. Chem (2000) 275:31938–31945.
   Google Scholar
• JACOBSSON SO, WALLIN T, FOWLER CJ: Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Marmara Exp. Ther (2001) 299:951–959.
   Google Scholar
• SARKER KP, BISWAS KK, TAMAKUCHI Metal: ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death. Neurochem. (2003) 85:50–61.
   PubMed Web of Science ®Google Scholar
• SARKER KP, OBARA S, NAKATA M, KITAJIMA I, MARUYAMA I: Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett. (2000) 472:39–44.
   PubMed Web of Science ®Google Scholar
• MACCARRONE M, ATTINA M, CARTONI A, BARI M, FINAZZI-AGRO A: Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J. Neurochem. (2001) 76:594–601.
   PubMed Web of Science ®Google Scholar
• PAGOTTO U, MARSICANO G, FEZZA F et al: Normal human pituitary gland and pituitary adenomas express cannabinoid receptor Type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. I. Clin. Endocrinol. Metab. (2001) 86:2687–2696.
   PubMed Web of Science ®Google Scholar
• LIGRESTI A, BISOGNO T, MATIAS I et al: Posssible endocannabinoid control of colorectal cancer growth. Gastroenterology (2003) 125:677–687.
   PubMed Web of Science ®Google Scholar
• ZHU LX, SHARMA S, STOLINA M et al: A-9-Tetrahydrocannabinol inhibits anti-tumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway../. Immunol (2000) 165:373–380.
   PubMed Web of Science ®Google Scholar
• TASHKIN DR, BALDWIN GC, SARAFIAN T, DUBINETT S, ROTH MD: Respiratory and immunologic consequences of marijuana smoking. Clin. Pharmacol (2002) 42:S71–S81.
   Google Scholar
• JORDA MA, RAYMAN N, VALK P, DE WEE E, DELWEL R: Identification, characterization and function of a novel oncogene: the peripheral cannabinoid receptor CB2. Ann. NY Acad. ScL (2003) 996:10–16.
   PubMed Web of Science ®Google Scholar
• JOOSTEN M, VALK PJ, JORDA MA et al: Leukemic predisposition of pSca-1/CB2 transgenic mice. Exp. Hematol (2002) 30:142–149.
   PubMed Web of Science ®Google Scholar
• MELCK D, BISOGNO T, DE PETROCELLIS L et al: Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CBI. receptors. Biochem. Biophys. Res. Commun. (1999) 262:275–284.
   PubMed Web of Science ®Google Scholar
• •Synthesis of novel antitumour agents to target the endocannabinoid system.
   Google Scholar
• DI MARZO V, BISOGNO T, MELCK D et al: Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. (1998) 436:449–454.
   PubMed Web of Science ®Google Scholar